B9-23E

B9-23E is a hybrid insulin peptide (HIP) that functions as a neo-antigen in the pathogenesis of Type 1 diabetes (T1D). It is formed by the covalent fusion of a fragment of the insulin B-chain (amino acids 9-23) with a dipeptide sequence derived from the C-peptide. These hybrid peptides are recognized by autoreactive T-cells and are thought to be more potent triggers of the autoimmune response than standard insulin peptides. Research presented at the ADA 2025 meeting suggests that B9-23E may play a dual role in the disease process; while it is a target for cellular immunity, it may also induce immunoregulatory responses (such as IL-10 production) during the early stages of T1D. This suggests that B9-23E or its derivatives could potentially be developed as an antigen-specific immunotherapy to prevent the progression of beta-cell destruction in Japanese and other Asian populations.

Other names

hybrid insulin peptide B9-23EHIP B9-23E